Transition Therapeutics Company Profile (NASDAQ:TTHI)

About Transition Therapeutics (NASDAQ:TTHI)

Transition Therapeutics logoTransition Therapeutics Inc. is a product-focused biopharmaceutical company. The Company's principal business activity is the researching and developing of therapeutic agents. The Company is developing therapeutics for central nervous system (CNS) and metabolic disease indications. The Company's technologies are focused on the treatment of agitation and aggression in Alzheimer's disease and diabetes. The Company's subsidiary, Transition Therapeutics Ireland Limited (Transition Ireland), is developing two drug candidates: neuropsychiatric candidate ELND005 and androgen deficiency candidate TT701. The Company's subsidiary, Waratah Pharmaceuticals Inc. (Waratah), is developing diabetes drug candidate TT401. The Company's other two entities provide development services in support of the clinical and non-clinical activities of Transition Ireland and Waratah.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:TTHI
  • CUSIP: N/A
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: $1.59
  • 200 Day Moving Avg: $1.11
  • 52 Week Range: $0.66 - $2.75
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.67
  • P/E Growth: 0.00
Misc:
  • Average Volume: 86,277 shs.
  • Beta: 1.59
 

Frequently Asked Questions for Transition Therapeutics (NASDAQ:TTHI)

What is Transition Therapeutics' stock symbol?

Transition Therapeutics trades on the NASDAQ under the ticker symbol "TTHI."

How were Transition Therapeutics' earnings last quarter?

Transition Therapeutics Inc (NASDAQ:TTHI) posted its quarterly earnings data on Tuesday, September, 15th. The company reported ($0.31) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.39) by $0.08. View Transition Therapeutics' Earnings History.

Who are some of Transition Therapeutics' key competitors?

How do I buy Transition Therapeutics stock?

Shares of Transition Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Transition Therapeutics stock cost?

One share of Transition Therapeutics stock can currently be purchased for approximately $1.52.

Analyst Ratings

Consensus Ratings for Transition Therapeutics (NASDAQ:TTHI) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Transition Therapeutics (NASDAQ:TTHI)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/14/2016Cowen and CompanyReiterated RatingHoldN/AView Rating Details
4/19/2016Canaccord GenuityReiterated RatingHoldN/AView Rating Details
(Data available from 5/23/2015 forward)

Earnings

Earnings History for Transition Therapeutics (NASDAQ:TTHI)
Earnings by Quarter for Transition Therapeutics (NASDAQ:TTHI)
Earnings History by Quarter for Transition Therapeutics (NASDAQ:TTHI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
9/15/2015Q415($0.39)($0.31)ViewN/AView Earnings Details
5/12/2015Q315($0.20)($0.11)ViewN/AView Earnings Details
2/10/2015($0.24)($0.38)ViewN/AView Earnings Details
11/12/2014Q312($0.18)($0.45)ViewN/AView Earnings Details
9/26/2014($0.28)($0.39)ViewN/AView Earnings Details
5/14/2014($0.07)($0.16)ViewN/AView Earnings Details
11/12/2013($0.11)($0.08)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Transition Therapeutics (NASDAQ:TTHI)
Current Year EPS Consensus Estimate: $-0.33 EPS
Next Year EPS Consensus Estimate: $-0.57 EPS

Dividends

Dividend History for Transition Therapeutics (NASDAQ:TTHI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Transition Therapeutics (NASDAQ:TTHI)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Transition Therapeutics (NASDAQ:TTHI)
Latest Headlines for Transition Therapeutics (NASDAQ:TTHI)
Source:
DateHeadline
finance.yahoo.com logoTransition Therapeutics Shareholders Approve Acquisition by OPKO Health
finance.yahoo.com - April 7 at 1:08 PM
finance.yahoo.com logoTransition Therapeutics Announces Special Shareholder Meeting Voting Results Including Shareholder Approval …
finance.yahoo.com - August 26 at 7:33 PM
streetinsider.com logoOPKO Health (OPK) Announces Transition Therapeutics (TTHI) Shareholder Approval of Proposed Acquisition
www.streetinsider.com - August 26 at 10:49 AM
finance.yahoo.com logo8:53 am Transition Therapeutics shareholders approve merger with OPKO health (OPK), transaction expected to close Sept 1
finance.yahoo.com - August 26 at 10:49 AM
finance.yahoo.com logoTransition (TTHI) Stock Up on News of Acquisition by Opko
finance.yahoo.com - July 1 at 8:59 AM
finance.yahoo.com logoTransition Therapeutics Announces Third Quarter Fiscal 2016 Financial Results
finance.yahoo.com - May 11 at 4:01 PM
finance.yahoo.com logoTransition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2016 Financial Results on Wednesday, May 11th, at 4:30 P.M. EST
finance.yahoo.com - May 9 at 4:01 PM
streetinsider.com logoTransition Therapeutics (TTHI) Commences Dosing in TT701 Phase 2 in Androgen Deficiency - StreetInsider.com
www.streetinsider.com - April 26 at 9:48 AM
finance.yahoo.com logoTransition Therapeutics Announces Dosing of First Patient in Phase 2 Study of Drug Candidate TT701
finance.yahoo.com - April 25 at 4:01 PM
nasdaq.com logoTransition: Lilly Not To Advance Diabetes Drug Candidate TT401 To Phase 3
www.nasdaq.com - April 18 at 9:57 AM
streetinsider.com logoTransition Therapeutics (TTHI) Says Lilly (LLY) Won't Advance TT401 into Phase 3
www.streetinsider.com - April 18 at 9:57 AM
thestreet.com logoTransition Therapeutics Provides Update On Type 2 Diabetes Drug Candidate TT401
www.thestreet.com - April 18 at 6:34 AM
finance.yahoo.com logoTransition Therapeutics Receives Notification From NASDAQ
finance.yahoo.com - March 17 at 5:01 PM
finance.yahoo.com logoTransition Therapeutics to Present at the 36th Annual Cowen Healthcare Conference
finance.yahoo.com - March 1 at 4:30 PM
finance.yahoo.com logoTransition Therapeutics Announces Second Quarter Fiscal 2016 Financial Results
finance.yahoo.com - February 9 at 4:30 PM
finance.yahoo.com logoTransition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2016 Financial Results on Tuesday, February 9th, at 4:30 P.M. EST
finance.yahoo.com - February 5 at 1:01 PM
finance.yahoo.com logoTransition Therapeutics Announces Top Line Phase 2 Clinical Study Results of Diabetes Drug Candidate TT401
finance.yahoo.com - February 1 at 6:01 AM
finance.yahoo.com logoTransition Therapeutics Announces Annual General Meeting Voting Results
finance.yahoo.com - January 6 at 6:01 AM
finance.yahoo.com logoTRANSITION THERAPEUTICS INC. Financials
finance.yahoo.com - December 8 at 1:15 PM
finance.yahoo.com logoTransition Therapeutics to Host Investor Day November 23 in New York
finance.yahoo.com - November 19 at 11:45 AM
finance.yahoo.com logoTransition Therapeutics Announces First Quarter Fiscal 2016 Financial Results
finance.yahoo.com - November 10 at 4:01 PM
finance.yahoo.com logoTransition Therapeutics to Hold Conference Call on First Quarter Fiscal 2016 Financial Results on Tuesday, November 10th, at 4:30 P.M. EST
finance.yahoo.com - November 2 at 6:01 AM
finance.yahoo.com logoTransition Therapeutics Announces Agreement for Phase 2 Study of TT701 Drug Candidate
finance.yahoo.com - October 29 at 4:01 PM

Social

Transition Therapeutics (TTHI) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by MarketBeat.com Staff